Outcomes of COVID-19 in patients with cystic fibrosis in Wales, UK was written by Lau, D.;Speight, L.;Melindo, F.;Prosser, A.;Lee, J.;Addy, C.;Duckers, J.;Ketchell, I.. And the article was included in Journal of Cystic Fibrosis in 2022.Application of 2492423-29-5 The following contents are mentioned in the article:
A review. Information is emerging on the clin. impact of the novel coronavirus, SARS-CoV-2, on people with cystic fibrosis (PwCF). This survey aims to characterize SARS-CoV-2 infection (COVID-19) in PwCF within the All Wales Adult Cystic Fibrosis Center (AWACFC). Patient data was retrospectively collated using electronic and written healthcare records. Age, sex, FEV1% pre-infection, chest radiograph (CXR) appearances, symptoms, clin. progress, CFTR modulator use, COVID-19 PCR results and COVID vaccination status were recorded. An AWACFC CF COVID-19 “Virtual Ward” management flowchart was established to standardise and optimize patient care. Thirty-eight PwCF in AWACFC had COVID-19 in 2020 (n = 10) and 2021 (n = 28). Of those infected, 20 (52%) were male, age range 17-50 yr, FEV1% range 38-113%, 26 (68%) were on CTFR modulators, with 4 (11%) post-lung transplant. Of the 2021 cohort (n = 28), 21 (75%) were fully vaccinated, 1 (4%) partially vaccinated, and 6 (21%) unvaccinated at time of infection. Most had mild-moderate symptoms, only 2 (5%) reportedly asymptomatic. Treatment varied: 24 (63%) required oral antibiotics at home (for symptoms or precautionary), 1 received antiviral molnupiravir, 4 (11%) required admission. Of the 4 admitted, 3 (75%)were post-lung transplant: 1 required pos. pressure oxygenation, 1 underwent extended invasive ventilation. Of those not admitted (n = 34) there was no change in post COVID-19 CXR appearances in 16 (47%), 3 (9%) registered CXR changes, the rest are awaiting follow-up CXR. There were no deaths or recorded reinfections. The contrast in COVID-19 incidence between 2020 and 2021 may reflect national shielding for clin. vulnerable groups in the UK in 2020, or emergence of new variants. The majority of PwCF had mild-moderate symptoms and good recovery from COVID-19. Most of those hospitalised were post-transplant, consistent with known risks in this clin. extremely vulnerable cohort. This study involved multiple reactions and reactants, such as ((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5Application of 2492423-29-5).
((2R,3S,4R,5R)-3,4-Dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate (cas: 2492423-29-5) belongs to tetrahydrofuran derivatives. Tetrahydrofuran (THF) is a Lewis base that bonds to a variety of Lewis acids such as I2, phenols, triethylaluminum and bis(hexafluoroacetylacetonato)copper(II). Oxidations have also proved to be valuable and efficient approaches to chiral tetrahydrofuran derivatives.Application of 2492423-29-5
Referemce:
Tetrahydrofuran – Wikipedia,
Tetrahydrofuran | (CH2)3CH2O – PubChem